p-8

Laminin B1 octapeptide P-8 is a synthetic laminin B1 chain octapeptide with laminin receptor binding ability.

TTP-8307 是一种抗病毒化合物，抑制鼻病毒和肠道病毒复制，通过干扰病毒 RNA 的合成抑制 coxsackievirus B3 病毒 和 poliovirus 病毒。TTP-8307 可用于研究病毒感染。

GP-82996 (CINK4) (CINK4) 是 CDK4 6的药理学抑制剂。GP-82996 对 CDK4 cyclin D1、CDK6 cyclin D1 和 Cdk5 p35 的 IC50s 分别为 1.5、5.6 和 25 μM。GP-82996 诱导肿瘤细胞 U2OS 的凋亡，可用于癌症研究。

CP-810123 是一种新的α 7 nAChR 激动剂，可用于治疗与精神分裂症和阿尔茨海默病等精神或神经疾病相关的认知障碍。

CP-866087 是一种新型、有效和选择性的μ阿片受体拮抗剂，用于研究女性性功能障碍。

CP-809101 hydrochloride 是选择性 5-HT2C 受体激动剂，对于人类 5-HT2C 5-HT2B 5-HT2A 受体。

NSP-805 是一种强心剂，是一种选择性的 phosphodiesterase 3 抑制剂，具有舒张血管的作用。

SP-8356 是一种有效的、口服活性的分化簇 147 (CD147) 抑制剂，具有抗动脉粥样硬化作用。

SPP-86 是有效的、选择性的RET 酪氨酸激酶抑制剂，其IC50=8 nM。它能够抑制 MCF7 细胞中 RET 诱导激活的 PI3K Akt 和 MAPK 信号通路，也能抑制 RET 诱导的 ERα 磷酸化。

ASP8731 作为一种选择性的BACH1抑制剂，能有效抑制炎症和血管闭塞，同时在镰状细胞病治疗中诱导胎儿血红蛋白的生成。

KP-81是一种结构复杂的芳香族化合物，可用于有机合成和药物设计。

GHP-88309 是一种口服有效的广谱抗副黏病毒 (paramyxoviruses) 剂，作用于病毒聚合酶 (viral polymerase)，干扰病毒 RNA 合成，并能够抑制呼吸道合胞病毒 (RSV)、麻疹病毒 (MeV) 和犬瘟热病毒 (CDV)，其EC50范围为0.06-1.2 μM。在小鼠模型中，GHP-88309 显示出抗感染活性。

cGMP-dependent protein kinase (PKG) inhibitor

CEP-8983 is a PARP inhibitor potentially for the treatment of solid tumours.

ASP8497 is a potent, long-acting DPP-IV inhibitor that improves glucose tolerance by elevating GLP-1 levels in a glucose-dependent insulin-stimulating manner. The compound is used as a therapeutic agent for impaired glucose tolerance and type 2 diabetes.

CP-85958 is a cysteinyl leukotriene antagonist.

CP-8668 is an orally active nonsteroidal progesterone receptor modulator with tetrahydrobenzoindolone skeleton.

CP-868388 free base (CP-868388) 是一种具有口服活性、有效性和选择性的 PPARα 激动剂，具有降血脂和抗炎活性，可用于研究血脂异常。

CP-8754 is a bio-active chemical. Detailed information has not been published.

SNAP-8719 is a selective antagonist of α1D-AR. SNAP-8719 showed better selectivity for α1D-AR and lower binding affinity for the 5-HT1A receptor.

Rp-8-bromo-Cyclic AMPS (Rp-8-bromo-cAMPS) is a cell-permeable cAMP analog that combines an exocyclic sulfur substitution in the equatorial position of the cyclophosphate ring with a bromine substitution in the adenine base of cAMP. It acts as an antagonist of cAMP-dependent protein kinases (PKAs) and is resistant to hydrolysis by cyclic nucleotide phosphodiesterases. Rp-8-bromo-cAMPS more effectively antagonizes cAMP-dependent activation of purified PKA type I from rabbit muscle than PKA type II from bovine heart.

Rp-8-CPT-cAMP is a structural combination of the lipophilic and non-hydrolyzable cAMP analogs, 8-CPT-cyclic AMP and Rp-cyclic AMPS .[1] It functions as a site-selective inhibitor of protein kinase A (PKA) type I and II, with preference towards site A of type I and site B of type II.2 By occupying cAMP binding sites at the regulatory subunit of PKA, Rp-8-CPT-cAMP prevents the kinase holoenzyme from dissociative activation.[2],[3]

Sp-8-CPT-cAMPS is a powerful and specific cAMP analog that activates cAMP-dependent protein kinase A (PKA I and PKA II) selectively and effectively. It exhibits a 153-fold preference for site A of RI over site A of RII, and a 59-fold preference for site B of RII over site B of RI.

Rp-8-CPT-cAMPS is a powerful and competitive antagonist of cAMP-induced activation of cAMP-dependent protein kinase (PKA) I and II. Acting as a potent cAMP analog, Rp-8-CPT-cAMPS exhibits a preference for site A of RI over site A of RII. Additionally, it favors site B of RII over site B of RI. This compound effectively inhibits cAMP-dependent PKA activation and demonstrates selectivity in binding to specific sites within the protein kinase.